Aerie Pharmaceuticals (AERI) 10-Q2017 Q1 Quarterly report

Filed: 3 May 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adding, analogue, asleep, Athlone, Award, billion, bimatoprost, cease, Codification, conjunctival, context, criteria, decline, deemed, desirable, diabetic, differentiating, Dublin, earliest, EITF, employment, equal, exceed, expand, expanded, expiration, expiring, feet, floor, forecast, Ganfort, guaranteed, highest, implicit, improve, incidence, inducement, infrastructure, interior, inventory, iv, jurisdiction, lack, listed, Listing, mechanism, modification, NASDAQ, neovascularization, night, nocturnal, owner, partnership, pilot, placebo, practical, produce, proliferative, promising, Protein, qualitative, rental, replacement, resubmission, resubmitted, retained, retinopathy, retrospective, Rule, satisfaction, seller, shell, showed, sourced, space, speak, spectrum, spent, square, supply, systemic, targeting, Task, tenant, thereto, TM, transition, typically, vivo, wholly

Removed: acquired, al, allegedly, amyloid, asserted, Aviv, axon, behalf, broadly, captioned, case, Cayman, cell, choice, commencing, complaint, Court, District, evolution, facilitate, false, finalize, gain, ganglion, governing, graybug, grow, incurring, Kelley, lawsuit, minimum, misleading, neuroprotection, November, occurred, offering, organized, partner, PDGFR, preservation, promote, publicly, purported, putative, Ramot, regeneration, retinal, shelf, software, state, submitted, supplementary, survival, taxable, Tel, University, unrelated, validation, VEGF

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

AERI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the filing of the Quarterly Report on Form 10-Q of Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for the period ended March 31, 2017 (the “Report”), the undersigned, Richard J. Rubino, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




Date: May 3, 2017				/s/ RICHARD J. RUBINO
				Richard J. Rubino
				Chief Financial Officer
				(Principal Financial and Accounting Officer)